About Journal of Pharmaceutical and BioTech Industry
Aims
Journal of Pharmaceutical and BioTech Industry (ISSN 2813-9380) is a peer-reviewed, open access journal dedicated to the dissemination of applied and translational research studies pertaining to the pharmaceutical and biotechnology sectors. Journal of Pharmaceutical and BioTech Industry aims to create a platform in which scientists and engineers from academia, industry, regulatory and other governmental agencies share and complement each other’s discoveries and advance science, engineering, and technology with the goal of enhancing patient wellbeing. All aspects of discovery, development, delivery, and manufacturing of drugs (drug substance, drug products including biodrugs, delivery devices, diagnostic agents, etc.) are covered.
We accept original research articles, critical and timely reviews, short communications, opinions, technical notes, reports, and expert perspectives. While studies performed by a single university, laboratory, or company are expected to be the norm, collaborative studies performed by multiple constituencies, e.g., academia–industry, academia–regulator, or academia–industry–regulator, are especially welcome, as are inter- or multi-disciplinary studies. The main criteria for publication are originality, high scientific quality and interest to the pharmaceutical and biotech industry sectors. Full experimental details and/or methods of study must be provided in the submitted research articles. We ask all our authors to carefully consider and declare any potential conflicts of interests.
Scope
The following list of topics is intended to indicate typical subjects that fall within the scope of the journal's interests:
- Early drug discovery and development;
- Product characterization and pre-clinical testing;
- Drug delivery systems and drug design;
- Active pharmaceutical ingredient (API) production;
- Formulation, device, and packaging development;
- Process development, optimization, scale-up, and manufacturing;
- Pharmaceutics and biopharmaceutics;
- Mathematical modeling, simulations, and digital twins;
- Pharmacokinetics, pharmacodynamics, and metabolism–transport of drugs;
- Pharmaceutical nanotechnology and biotechnology;
- Natural products and green chemistry;
- Toxicology;
- Clinical trials;
- Regulatory and legislative approval;
- Patent analysis.
MDPI Publication Ethics Statement
MDPI is a member of the Committee on Publication Ethics (COPE).
MDPI takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure to add
high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, inappropriate
authorship credit, and the like, do arise. MDPI takes such publishing ethics issues very seriously and our editors are trained to proceed in
such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use iThenticate to check submissions against previous publications.
Book Reviews
Authors and publishers are encouraged to send review copies of their recent related books to the following address. Received books will be listed as Books Received within the journal's News & Announcements section.
MDPI
Grosspeteranlage 5
CH-4052 Basel
Switzerland
Copyright / Open Access
Articles published in JPBI will be Open-Access articles distributed under the terms and conditions of the Creative Commons Attribution License (CC BY). The copyright is retained by the author(s). MDPI will insert the following note at the end of the published text:
Reprints may be ordered. Please contact for more information on how to order reprints. Announcements regarding academic activities such as conferences are published for free in the News & Announcements section of the journal. Advertisement can be either published or placed on the pertinent website. Contact e-mail address is . For further MDPI contacts, see here.Reprints
Announcement and Advertisement
Editorial Office
Contact us
